Clinical Trials Logo

Bipolar II clinical trials

View clinical trials related to Bipolar II.

Filter by:
  • None
  • Page 1

NCT ID: NCT01932541 Withdrawn - Bipolar Disorder Clinical Trials

Open-Label Study of Latuda for the Treatment of Mania in Children and Adolescents 6-17 Years Old

Start date: January 2017
Phase: Phase 4
Study type: Interventional

This study is an 8-week open-label trial testing Lurasidone (Latuda®) as a treatment for mania in children and adolescents with Bipolar I, Bipolar II, and Bipolar Spectrum disorders. We hypothesize that Lurasidone will be safe, tolerable, and effective in improving the core symptoms of bipolar disorders in children and adolescents ages 6-17.

NCT ID: NCT00709202 Completed - Schizophrenia Clinical Trials

Efficacy and Tolerability Study of Betahistine to Ameliorate Antipsychotic Associated Weight Gain

Start date: July 2008
Phase: Phase 2
Study type: Interventional

The study attempts to evaluate a histamine analog long used for the treatment of Meniere's disease, betahistine, that shows promise in reversing the antihistaminergic effects thought to be involved in antipsychotic induced weight gain. Hypothesis to be tested: A. Patients who have gained a developmentally inappropriate amount of weight on antipsychotics (AP) will see their weight and BMI decrease with betahistine augmentation as compared to placebo augmentation. B. Betahistine augmentation in AP treated patients will increase levels of satiety in a standardized meal situation and decrease caloric intake as compared to placebo augmentation. C. Metabolic effects of betahistine augmentation in AP treated patients will be reflected in differences in waist circumference, hip circumference and waist hip ratios D. Betahistine augmentation in this population will lead to decrease in fasting glucose-lipid lab values related to the development of metabolic syndrome as compared to placebo augmentation